The global market for In Vivo Contract Research Organization (CRO) was valued at US$5.3 Billion in 2024 and is projected to reach US$8.0 Billion by 2030, growing at a CAGR of 6.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and what they mean for your business.
Segments: Modality (Smalll Molecules Modality, Large Molecules Modality); Model Type (Rodent-based Model, Non-Rodent based Model); Application (Oncology Application, CNS Application, Diabetes Application, Obesity Application, Pain Management Application, Other Applications).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global In Vivo Contract Research Organization (CRO) Market - Key Trends and Drivers Summarized
Why Is In Vivo Contract Research Organization (CRO) Crucial for Preclinical and Clinical Research?
In vivo Contract Research Organizations (CROs) are essential for conducting preclinical and clinical research in drug development, focusing on studies conducted within living organisms. These CROs provide services such as animal testing, pharmacokinetics, toxicology, and efficacy studies that are vital to the early stages of drug development. In vivo studies help assess how a drug behaves in a biological system, providing critical data on its safety, bioavailability, and potential therapeutic effects. Outsourcing these services to specialized CROs allows pharmaceutical and biotechnology companies to reduce costs, accelerate research timelines, and access expertise in regulatory compliance and animal testing protocols, making in vivo CROs indispensable in the development pipeline.How Are Technological Advancements Shaping the In Vivo CRO Market?
Technological advancements in imaging, genomics, and data analytics are significantly enhancing the capabilities of in vivo CROs. Non-invasive imaging techniques, such as MRI, PET, and CT scans, have improved the ability to monitor drug effects and disease progression in real-time, providing more precise and detailed insights into drug efficacy and toxicity. Furthermore, advancements in genetic engineering and CRISPR technology have expanded the use of animal models, allowing for more targeted studies on specific diseases or genetic conditions. Data analytics and AI are also revolutionizing the in vivo CRO landscape by enabling faster and more accurate analysis of preclinical data, reducing the time it takes to make critical decisions in the drug development process.How Do Market Segments Define the Growth of the In Vivo CRO Market?
Service types include toxicology, pharmacokinetics, pharmacodynamics, and efficacy studies, with toxicology services accounting for the largest market share due to regulatory requirements for drug safety testing. Therapeutic areas served by in vivo CROs include oncology, cardiovascular diseases, infectious diseases, and neurological disorders, with oncology leading the market as cancer remains a primary focus of drug development. End-users include pharmaceutical companies, biotechnology firms, and academic institutions, with pharmaceutical companies being the dominant segment due to their high demand for outsourced preclinical services. The market is also expanding in emerging regions, where CRO services are increasingly outsourced to countries with lower operational costs.What Factors Are Driving the Growth in the In Vivo CRO Market?
The growth in the in vivo CRO market is driven by several factors, including increasing demand for preclinical and clinical research, the rising complexity of drug development, and the growing trend of outsourcing research activities. As pharmaceutical companies face mounting pressure to bring new drugs to market faster and more cost-effectively, they are turning to specialized CROs to handle in vivo studies, reducing the burden on internal resources. The growing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, is driving demand for in vivo studies to develop new therapeutics. Additionally, advancements in personalized medicine and biologics are increasing the complexity of preclinical research, making CROs a critical component of the drug development process.Report Scope
The report analyzes the In Vivo Contract Research Organization (CRO) market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.Segments: Modality (Smalll Molecules Modality, Large Molecules Modality); Model Type (Rodent-based Model, Non-Rodent based Model); Application (Oncology Application, CNS Application, Diabetes Application, Obesity Application, Pain Management Application, Other Applications).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Smalll Molecules Modality segment, which is expected to reach US$5.4 Billion by 2030 with a CAGR of a 5.8%. The Large Molecules Modality segment is also set to grow at 9.5% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $1.4 Billion in 2024, and China, forecasted to grow at an impressive 6.8% CAGR to reach $1.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global In Vivo Contract Research Organization (CRO) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global In Vivo Contract Research Organization (CRO) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global In Vivo Contract Research Organization (CRO) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as American Preclinical Services, LLC., Charles River Laboratories, Covance Inc., Evotec (US), Inc., ICON Plc and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 34 companies featured in this In Vivo Contract Research Organization (CRO) market report include:
- American Preclinical Services, LLC.
- Charles River Laboratories
- Covance Inc.
- Evotec (US), Inc.
- ICON Plc
- inVentiv Health
- Parexel International
- Pharmaceutical Product Development, LLC (PPD)
- Quintiles
- Theorem Clinical research
- WuXi AppTec, Inc.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- American Preclinical Services, LLC.
- Charles River Laboratories
- Covance Inc.
- Evotec (US), Inc.
- ICON Plc
- inVentiv Health
- Parexel International
- Pharmaceutical Product Development, LLC (PPD)
- Quintiles
- Theorem Clinical research
- WuXi AppTec, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 89 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5.3 Billion |
| Forecasted Market Value ( USD | $ 8 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
